Compare Abeona Therapeutics Inc (ABEO) vs Broadcom Inc (AVGO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Broadcom Inc — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Broadcom Inc trades at $392.99 (market cap $1.76T). The key difference: Broadcom Inc is far larger — about 4714.5× Abeona Therapeutics Inc's market cap, and Broadcom Inc pays a 0.7% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | AVGO | |
|---|---|---|
Market Cap | $373.32M | $1.76T |
Sector | Health | Technology |
52-Week High | $7.23 | $481.57 |
52-Week Low | $4.17 | $271.80 |
Enterprise Value | $228.22M | $1.81T |
Dividend Yield | — | 0.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Broadcom (AVGO) trades at $370.78, up 2.87% today but remains in a bearish technical trend, 25% below its 52-week high. The company demonstrates strong fundamentals with Q1 2026 EPS beating estimates at $2.44 and robust revenue growth from $51.6B in 2024 to $63.9B in 2025. Recent news highlights a strategic partnership extension with Apple through 2031 for custom AI chips, providing long-term revenue visibility amid a challenging market environment for semiconductor stocks.
AVGO presents a compelling investment case with strong analyst support (88% buy ratings) and a $510.43 consensus price target representing 38% upside. However, elevated valuation multiples (P/E 62.21, P/S 24.17) and technical bearish signals warrant caution. The key opportunity lies in AVGO's AI semiconductor growth (143% YoY to $10.8B last quarter) while risks include market volatility and competitive pressures in the chip sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Broadcom Inc
Broadcom--the combined entity of Broadcom and Avago--boasts a highly diverse product portfolio across an array of end markets. Avago focused primarily on radio frequency filters and amplifiers used in high-end smartphones, such as the Apple iPhone and Samsung Galaxy devices, in addition to an assortment of solutions for wired infrastructure, enterprise storage, and industrial end markets. Legacy Broadcom targeted networking semiconductors, such as switch and physical layer chips, broadband products (such as television set-top box processors), and connectivity chips that handle standards such as Wi-Fi and Bluetooth. The company has acquired Brocade, CA Technologies, Symantec's enterprise security business, and has a pending deal to acquire VMware to bolster its offerings in software.
Read more on AVGO →
